CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
Provided By GlobeNewswire
Last update: Apr 9, 2025
SOUTH SAN FRANSCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces its first clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025.
Read more at globenewswire.com0.8901
-0.22 (-19.81%)
Find more stocks in the Stock Screener
CERO Latest News and Analysis
2 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
2 days ago - ChartmillTop stock movements in today's session.Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.
3 days ago - ChartmillThursday's session: top gainers and losersHere are the top movers in Thursday's session, showcasing the stocks with significant price changes.
3 days ago - ChartmillKeep an eye on the top gainers and losers in Thursday's session.Curious about what's happening in today's session? Check out the latest stock movements and price changes.
3 days ago - ChartmillWhich stocks are gapping on Thursday?In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down.
